We use cookies to personalize content, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. For information on how to change your cookie settings, please see our Privacy policy. Otherwise, if you agree to our use of cookies, please continue to use our website.

Kent Groves, PhD

Vice President Global Health Strategy, Health,

Kent is a Senior Vice President of Strategy, and leads Merkle’s Global Health Strategy practice. He has been consulting in the areas of pharmaceutical and animal health strategy for more than 20 years. He is published extensively in a variety of journals including, Research in Social and Administrative Pharmacy, Formulary, the Journal of Clinical Pharmacy and Therapeutics, and the Journal of Database Marketing. Kent is recognized as a subject matter expert in the area of factors influencing physician prescribing, is the author of several white papers, and most recently was the lead author for the chapter on Prescribing Behavior in Social and Behavioral Aspects of Pharmaceutical Care, 3rd Edition, published in 2016.

 

Kent has worked with a number of clients in the pharmaceutical, healthcare, and animal health vertical including Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Elanco, Gilead, GSK, Merck,  Novartis,  and Sanofi (Genzyme, Chattem and Merial), focusing on engagement and communication strategy in the US, Canada, Europe and Australasia. He has a PhD in Pharmaceutical Strategy and Policy from Dalhousie University in Halifax, NS, and holds the position of Assistant Professor, Clinical Pharmacy, at the James L Winkle College of Pharmacy, University of Cincinnati.

Kent's Articles, Blog Posts, Webinars and More

Blog We suggest...

Leveraging HCP Migration to Optimize Multi-Channel Spend

One of the biggest challenges that launch brands in unique therapeutic areas face is identifying the right target audience for both unbranded and branded messaging. The right audience can impact speed to market, awareness and trial, business impact, and ROI.
Blog We suggest...

What Does the Future Hold for Peer Reviewed Medicine?

Would you prescribe a drug just because other doctors “like” it? There are indications that this may already be happening, and health marketers should start thinking about what that means for them.
Blog We suggest...

How Would You Rate Your Communications to HCPs?

It is critical to move away from an ad hoc approach incorporating email into your campaign strategy, and to take a more analytic approach to the frequency, content, cadence, and targeting of your overall email communication.
Topics:
Blog We suggest...

The New Role of the Pharma Rep and Raising the Digital Stakes

Given the rapidly evolving changes to our healthcare system, as well as the overwhelming volume of content that healthcare professionals (HCP) are faced with daily across channels, a defined HCP communication strategy at the therapeutic and brand level is more important than ever for the pharmaceutical indust
Blog We suggest...

Non-Personal Promotion Is Ready to Take the Spotlight

Like the substitution for the star forward, or the lead actor in a Broadway hit, non-personal promotion (NPP) is ready to take center stage in targeted physician communications. Physicians, like consumers, have an evoked set of brands to which they refer in most situations.
Blog We suggest...

2016 Is Around the Corner, Are There Gaps in Your Target Audience Strategy?

With access to physicians continuing to shrink, and pressure mounting for physicians themselves (and their associated clinics) to reduce costs and increase efficiency, it is time to really expand our focus to include one of the fastest-growing groups of professionals in the clinical space, namely nurse practi
Blog We suggest...

The 4 Ps of Marketing

Many years ago, as a marketing professor teaching Introductory Marketing to the open minds of first and second-year business and commerce students, my task at hand was fairly straightforward.